Label: Information for the User
Alphagan 2 mg/ml
eye drops in solution.
brimonidine tartrate
Read this label carefully before starting to use the medicine, as it contains important information for you.
Alphagan is used to reduce intraocular pressure. The active ingredient in Alphagan is brimonidine tartrate, which belongs to a group of medications called alpha-2 adrenergic receptor agonists and works by reducing pressure in the eyeball.
It can be used alone when beta-blocker eye drops are contraindicated, or with other eye drops, when the medication alone is not sufficient to reduce an increase in intraocular pressure in the treatment of open-angle glaucoma or ocular hypertension.
Warnings and precautions
Speak with your doctor before using Alphagan:
Children and adolescents
Alphagan is not recommended for use in children between 2 and 12 years of age.
Alphagan should not be used generally in adolescents from 12 to 17 years, as no clinical studies have been conducted in this age group.
Other medications and Alphagan
Inform your doctor or pharmacist if you are using or have used recently other
medications, including those purchased without a prescription.
Inform your doctor if you are using any of the following medications:
These may affect your treatment with Alphagan.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medication. Do not use Alphagan if you are pregnant unless your doctor considers it necessary.
Alphagan should not be used during breastfeeding.
Driving and operating machinery
Alphagan contains benzalkonium chloride
This medication contains 0.25 mg of benzalkonium chloride in each 5 ml of solution, equivalent to 0.05 mg/ml.
Benzalkonium chloride can be absorbed by soft contact lenses, altering their color. Remove contact lenses before using this medication and wait 15 minutes before reinserting them.
Benzalkonium chloride may cause eye irritation, especially if you have dry eye or other corneal diseases (transparent layer at the front of the eye). Consult your doctor if you feel a strange sensation, burning, or pain in the eye after using this medication.
Follow exactly the administration instructions for Alphagan indicated by your doctor. Consult your doctor or pharmacist if you have any doubts.
Adults
The recommended dose is one drop twice a day in the affected eye(s), approximately with 12 hours of difference. Do not change the dose or stop using Alphagan without talking to your doctor.
Children under 12 years
Alphagan should not be used in children under 2 years of age.
Alphagan is not recommended for use in children between 2 years and 12 years of age.
Usage instructions
Alphagan is presented as eye drops. Always wash your hands before applying the eye drops. Your prescription indicates how many drops you should use in each dose. If you use Alphagan with another eye drop, wait 5-15 minutes before applying the second eye drop.
Apply your eye drops as follows:
If the drop falls outside the eye, try again.
To avoid contamination, do not let the dropper tip touch the eye or any other surface.
Replace the cap and close the container immediately after use.
If you use moreAlphaganthan you should
Adults
In adults who applied more drops than prescribed, the reported adverse effects were those already known with Alphagan.
Adults who accidentally ingested Alphagan experienced a decrease in blood pressure, which in some patients was followed by an increase in blood pressure.
Children
Severe adverse effects were reported in children who accidentally ingested Alphagan. The symptoms included drowsiness, hypotonia, low body temperature, pallor, and breathing difficulties. If this happens, contact your doctor immediately.
Adults and children
If Alphagan has been accidentally ingested or if more Alphagan than prescribed has been used, please contact your doctor immediately.
If you forget to use Alphagan
If you forget to administer a dose, apply it as soon as you remember. However, if it is almost time for your next dose, you should completely omit the missed dose and then follow your regular schedule. Do not use a double dose to compensate for the missed doses.
If you interrupt treatment withAlphagan
For Alphagan to be effective, it must be used every day. Do not stop using Alphagan until your doctor tells you to.
If you have any doubts about the use of this product, ask your doctor or pharmacist.
The following side effects may be observed with Alphagan.
Those affecting the eye
Very common(may affect more than 1 in 10 people):
Common(may affect up to 1 in 10 people):
Very rare(may affect up to 1 in 10,000 people)::
Frequency unknown(the frequency cannot be estimated from the available data):
Those affecting the body:
Very common(may affect more than 1 in 10 people)::
Common(may affect up to 1 in 10 people):
Uncommon(may affect up to 1 in 100 people):
Rare(may affect up to 1 in 1,000 people):
Very rare(may affect more than 1 in 10,000 people):
Frequency unknown(the frequency cannot be estimated from the available data):
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use: www.notificaRAM.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Medications should not be thrown down the drains or in the trash. Deposit the containers and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and medications you no longer need. By doing so, you will help protect the environment.
Composition of Alphagan
Appearance of Alphagan and contents of the packaging
Alphagan is a clear yellowish-green to slightly yellowish-green solution in a plastic bottle.
Each bottle contains 2.5 ml, 5 ml, or 10 ml of the medication.
Alphagan is available in packs of 1, 3, or 6 bottles.
Not all packaging may be marketed.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization:
AbbVie Spain, S.L.U.
Avenida de Burgos 91
28050, Madrid
Spain
Responsible for manufacturing:
Allergan Pharmaceuticals Ireland,
Westport, Co. Mayo,
Ireland
This medication is authorized in the member states of the European Economic Area with the following names:
Austria | Alphagan 0.2% Augentropfen |
Germany | Alphagan 0.2% m/V (2 mg/ml) Augentropfen |
Belgium, Finland, Greece, Iceland, Luxembourg, Norway, Portugal | Alphagan |
Denmark, Ireland, Italy, Netherlands, Sweden, United Kingdom | Alphagan 0.2% |
France | ALPHAGAN 0,2% (2mg/ml), collyre en solution |
Spain | Alphagan 2 mg/ml colirio en solución |
This leaflet was approved in 09/2020
The detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.